Preeclampsia in pregnancy – prediction, prevention and further management

Česká verzia

Authors: S. Leahomschi; P. Calda
Authors place of work: Gynekologicko-porodnická klinika VFN a 1. LF UK, Praha, přednosta prof. MUDr. A. Martan, DrSc.
Published in the journal: Ceska Gynekol 2014; 79(5): 356-362

Summary

Review article about preeclampsia (PE), analysis and summarization of cutting-edge knowledge about this adverse pregnancy outcome based on the study of existing literature. A relatively new trend is the prediction possibility of the development of PE in early gestation and appropriate management of high risk pregnancies. In this paper we accord special attention to this important aspect. On the other hand possibilities and efficiency of prevention of PE are discussed.

Prediction, prevention, early diagnosis and appropriate treatment of PE are important goals of the modern obstetrics.

Keywords:
preeclampsia, screening, prediction, PlGF, sFlt-1, prevention, Aspirin

Zdroje

1. Ahmad, S., et al. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res, 2004, 95, p. 884–891.

2. Akolekar, R., Syngelaki, A., Poon, L., et al. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther, 2013, 33(1), p. 8–15.

3. Alahakoon, TI., et al. Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro- and anti-angiogenic profiles. J Matern Fetal Neonatal Med, 2014, Feb 3. [Epub ahead of print]

4. Alanis, MC., Robinson, CJ., Hulsey, TC., et al. Early-onset severe preeclampsia: induction of labor vs elective cesarean delivery and neonatal outcomes. Am J Obstet Gynecol, 2008, 199, p. 262.e1–262.e6.

5. Al-Jameil, N., et al. A brief overview of preeclampsia. J Clin Med Res, 2014, 6(1), p. 1–7.

6. Audibert, F., Boucoiran, I., An, N., et al. Screening for preeclampsia using firsttrimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynecol, 2010, 203, 383, p. e1–8.

7. Brennan, LJ., et al. Vascular dysfunction in preeclampsia. Microcirculation, 2014, 21(1), p. 4–14.

8. Bujold, E., Roberge, S., Lacasse, Y., et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol, 2010, 116, p. 402–414.

9. Caritis, S., et al. Low-dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med, 1998, 338(11), p. 701–705.

10. Cnossen, JS., Morris, RK., ter Riet, G., et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ, 2008, 1768, p. 701–711.

11. Di Sessa, TG., et al. Cardiac function in fetuses and newborns exposed to low-dose aspirin during prengancy. Am J Obstet Gynecol, 1994, 171(4), p. 892–900.

12. Duley, L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol, 2009, 33(3), p. 130–137.

13. Duley, L., et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007 Apr 18, (2):CD004659.

14. Erez, O., et al. Preeclampsia in twin gestations: association with IVF treatments, parity and maternal age. J Matern Fetal Neonatal Med, 2006, 19(3), p. 141–146.

15. Escudero, C., et al. Impaired adenosine-mediated angiogenesis in preeclampsia: potential implications for fetal programming. Front Pharmacol, 2014, 5, p. 134.

16. Espinoza, J. Recent biomarkers for the identification of patients at risk for preeclampsia: the role of uteroplacental ischemia. Expert Opin Med Diagn, 2012, 6(2), p. 121–130.

17. Geographic variation in the incidence of hypertension in pregnancy. World Health Organization International Collaborative Study of Hypertensive Disorders of Pregnancy. Am J Obstet Gynecol, 1988, 158(1), p. 80–83.

18. Gilbert, J., et al. Recombinant VEGF-121 infusion lowers blood pressure and improves renal function in rats with placental ischemia-induced hypertension. Hypertension, 2010, 55(2), p. 380–385.

19. Hernandez-Diaz, S., et al. Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. BMJ, 2009, 338, p. 2255.

20. Hutcheon, JA., et al. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol, 2011, 25(4), p. 391–403.

21. Jacquemyn, Y., Zemtsova, O. Risk factors and prediction of preeclampsia. Acta Clin Belg, 2010, 65(1), p. 1–12.

22. Jeyabalan, A. Epidemiology of preeclampsia: impact of obesity. Nutr Rev, 2013, 71, Suppl 1, p. S18–25.

23. Khan, KS., et al. WHO analysis of causes of maternal death: a systematic review. Lancet, 2006, 367(9516), p. 1066–1074.

24. Klebanoff, MA., Berendes, HW. Aspirin exposure during the first 20 weeks of gestation and IQ at four years of age. Teratology, 1988, 37(3), p. 249–255.

25. Kuc, S., Wortelboer, EJ., van Rijn, BB., et al. Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review. Obstet Gynecol Surv, 2011, 66, p. 225–239.

26. Kumasawa, K., et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. PNAS, 2011, 108(4), p. 1451–1455.

27. Levine, RJ., Maynard, SE., Qian, C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med, 2004, 350, p. 672–683.

28. Maynard, SE., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension and proteinuria in preeclampsia. J Clin Invest, 2003, 111(5), p. 649–658.

29. Myatt, L. Placental adaptive responses and fetal programming. J Physiol, 2006, 572(Pt 1), p. 25–30.

30. Nicolaides, K. Combined screening for intermediate and late onset pre-eclampsia at 30–33 weeks of gestation. Oral communication. ISUOG: 22nd World Congress on Ultrasound in Obstetrics and Gynecology 2012/59. DGGG-Kongress 2012.

31. Norgard, B., et al. Aspirin use during early pregnancy and the risk of congenital abnormalities: a population-based case-control study. Am J Obstet Gynecol, 2005, 192(3), p. 922–923.

32. Papageorghiou, AT., Yu, CK., Bindra, R., et al. Fetal Medicine Foundation Second Trimester Screening Group: Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol, 2001, 18, p. 441–449.

33. Poon, LC., Akolekar, R., Lachmann, R., et al. Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11–13 weeks. Ultrasound Obstet Gynecol, 2010, 35, p. 662–670.

34. Roberge, S., Giguère, Y., Villa, P., et al. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol, 2012, 29, p. 551–556.

35. Roberge, S., Villa, P., Nicolaides, K., et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther, 2012, 31, p. 141–146.

36. Rosser, ML., Katz, NT. Preeclampsia: an obstetrician’s perspective. Adv Chronic Kidney Dis, 2013, 20(3), p. 287–296.

37. Rotchell, YE., et al. Barbados low dose aspirin study in pregnancy (BLASP): a randomized trial for the prevention of pre-eclampsia and its complications. Br J Obstet Gynaecol, 1998, 105(3), p. 286–292.

38. Sattar, N., Greer, IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? BMJ, 2002, 325(7356), p. 157–160.

39. Schiessl, B., et al. Prenatal constriction of the fetal ductus arteriosus – relatated to maternal pain medication? Z Geburtshilfe Neonatol, 2005, 209(2), p. 65–68.

40. Sibai, B., et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. N Engl J Med, 1993, 329(17), p. 1213–1218.

41. Sibai, B., Dekker, G., Kupferminc, M. Pre-eclampsia, Lancet, 2005, 365, p. 785–799.

42. Sibai, BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol, 2003, 102, p. 181–192.

43. Silasi, M., et al. Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia. Obstet Gynecol Clin North Am, 2010, 37(2), p. 239–253.

44. Slone, D., et al. Aspirin and congenital malformations. Lancet, 1976, 1(7974), p. 1373–1375.

45. Spencer, K., Yu, CK., Savvidou, M., et al. Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free beta-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks‘ gestation. Ultrasound Obstet Gynecol, 2006, 2, p. 658–663.

46. Stepan, H., Unversucht, A., Wessel, N., et al. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension, 2007, 49, p. 818–824.

47. Stocks, G. Preeclampsia: pathophysiology, old and new strategies for management. Eur J Anaesthesiol, 2014, 31(4), p. 183–189.

48. Szostak-Wegierek, D., Szamotulska, K. Fetal development and risk of cardiovascular diseases and diabetes type 2 in adult life. Med Wieku Rozwoj, 2011, 15(3), p. 203–215.

49. Thadhani, R., et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation, 2011, 124(8), p. 940–950.

50. Verlohren, S., et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol, 2012, 206, 58e1–8.

51. Wagner, SJ., et al. From placenta to podocyte: vascular and podocyte pathophysiology in preeclampsia. Clin Nephrol, 2012, 78(3), p. 241–249.

52. Werler, MM., Mitchell, AA., Shapiro, S. The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med, 1989, 321(24), p. 1639–1642.

53. Wyatt-Ashmead, J. Antenatal closure of the ductus arteriosus and hydrops fetalis. Pediatr Dev Pathol, 2011, 14(6), p. 469–474.